Benefits
Sinusitis and Upper Respiratory Inflammation
Mazzone 1990 and others showed serrapeptase reduces sinusitis symptoms (pain, nasal secretion, obstruction, swelling) compared to placebo. Used widely in Italy, Japan, India for chronic sinusitis adjunct. Mechanism: liquefying mucus and reducing inflammatory mediators.
Post-Surgical Edema and Pain
Multiple trials (especially in oral/maxillofacial surgery, orthopedic procedures) show serrapeptase reduces post-operative swelling and pain vs placebo. Tachibana 1984 wisdom tooth surgery trial foundational. Used routinely in Japan post-operatively.
Fibrocystic Breast Disease
Kee 1989 RCT showed serrapeptase (5 mg TID) reduced breast pain, swelling, and induration in fibrocystic breast disease vs placebo. Limited subsequent replication but referenced in supplement marketing.
Carpal Tunnel Syndrome (Limited Evidence)
Panagariya 1999 small trial suggested serrapeptase improves carpal tunnel symptoms. Sample size limited; not standard treatment (which includes wrist splinting, NSAIDs, corticosteroid injection, surgery for refractory cases).
Atherosclerosis Plaque (Theoretical)
Theoretical mechanism: serrapeptase digests atherosclerotic plaque protein components. Marketed for cardiovascular health based on this mechanism. NO human clinical evidence demonstrating cardiovascular outcomes benefit. Speculative claim.
Mechanism of action
Selective Proteolytic Activity
Serrapeptase digests dead/inflammatory tissue and proteins (fibrin, bradykinin, histamine, C-reactive protein) but not healthy tissue. Selective activity attributed to enzyme's substrate specificity for inflammatory mediators.
Bradykinin Reduction
Bradykinin is a major inflammatory mediator causing pain, edema, vasodilation. Serrapeptase degrades bradykinin — basis for anti-inflammatory and analgesic effects.
Mucolytic Activity
Serrapeptase breaks down mucoprotein matrix in respiratory mucus — reducing viscosity. Basis for sinusitis, bronchitis, COPD adjunctive use.
Enteric Coating Required
Serrapeptase is destroyed by gastric acid — requires enteric coating to deliver intact enzyme to small intestine for absorption. Quality varies dramatically by manufacturer; non-enteric-coated products may be ineffective.
Clinical trials
Multicenter trial of serrapeptase (15 mg BID) vs placebo for chronic sinusitis in 193 patients for 7 days. (Mazzone 1990, J Int Med Res)
193 chronic sinusitis patients.
Serrapeptase significantly reduced sinusitis symptom scores (pain, nasal secretion, obstruction, swelling) vs placebo. Foundational European trial supporting clinical use in sinusitis.
RCT of serrapeptase vs placebo for post-operative swelling after wisdom tooth surgery.
Wisdom tooth extraction patients.
Serrapeptase significantly reduced post-operative edema and pain vs placebo. Foundational trial supporting routine post-surgical use in Japan and Europe.
About this ingredient
Serrapeptase (serratiopeptidase) is a PROTEOLYTIC ENZYME originally isolated from Serratia E15 bacteria found in silkworm intestines — the enzyme silkworms use to dissolve their cocoons. Now commercially produced via fermentation. Standardized in ENZYMATIC UNITS (typically 20,000-80,000 SPU/serving) — typical clinical dose: 10-30 mg/day.
CRITICAL FORMULATION REQUIREMENT: serrapeptase is destroyed by gastric acid; products MUST use enteric coating to deliver intact enzyme to small intestine for absorption. Non-enteric-coated products may be ineffective — verify enteric coating on label. CLINICAL/REGULATORY STATUS: prescription drug or OTC drug in Japan, India, and parts of Europe (where it's been used clinically since the 1960s). In the US, supplement only — not FDA-approved drug. JAPANESE MHLW historically revoked some serrapeptase indications based on lack of robust efficacy data in newer rigorous trials — adds nuance to evidence base.
EVIDENCE-BASED USES: (1) Chronic sinusitis adjunct (Mazzone 1990; clinical practice in Europe/Japan); (2) Post-surgical edema and pain (Tachibana 1984; Japanese routine use); (3) Fibrocystic breast disease (Kee 1989); (4) Carpal tunnel syndrome (Panagariya 1999, limited); (5) Bronchitis, COPD adjunct (mucolytic effect); (6) Joint inflammation (modest evidence). MARKETING CLAIMS exceed evidence: (7) ATHEROSCLEROSIS PLAQUE — theoretical only, no human cardiovascular outcome data; (8) BIOFILM DISRUPTION — emerging research, clinical translation unclear.
CRITICAL CAUTIONS: (1) PNEUMONITIS — RARE but documented in Japanese pharmacovigilance; interstitial pneumonia cases reported; serious adverse event; if respiratory symptoms develop, discontinue and seek medical evaluation; (2) BLEEDING RISK — proteolytic activity carries theoretical bleeding risk; AVOID with anticoagulants/antiplatelets without medical supervision; pre-surgery discontinuation 1-2 weeks; (3) ACTIVE BLEEDING, RECENT TRAUMA, GI ULCERS — AVOID; (4) PREGNANCY/LACTATION — insufficient safety data; AVOID; (5) ENTERIC COATING — verify product has enteric coating; non-coated forms may be ineffective; (6) JAPANESE MHLW REGULATORY HISTORY — added skepticism to some marketed claims; rigorous Western RCTs limited; (7) For CHRONIC SINUSITIS, evidence-based care includes saline irrigation, topical corticosteroids, antibiotics for bacterial cases, surgical evaluation for refractory; serrapeptase adjunctive at most; (8) For POST-SURGICAL EDEMA, ice, elevation, NSAIDs (when appropriate), and time remain primary; serrapeptase adjunctive in some surgical practices; (9) DOSE — start low (10 mg) and increase if tolerated; on empty stomach; (10) The 'silkworm enzyme that digests scar tissue and atherosclerotic plaque' marketing is colorful but oversimplified.